No Data
Express News | Wantai Biological Pharmacy Says Unit and GSK End Cooperation on Development and Commercialization of Hpv9-as04 Vaccine Candidate
Beijing Wantai Biological Pharmacy Enterprise (603392.SH): Termination of Cooperation Agreement with GSK by its wholly-owned subsidiary.
On July 22, Gelun Hui reported that Beijing Wantai Biological Pharmacy Enterprise (603392.SH) announced that, after friendly consultations, both parties have decided to discontinue the development and commercial cooperation of the HPV9-AS04 candidate vaccine under the "Cooperation Agreement" and signed a "Cooperation Agreement" termination letter on July 20, 2024. Both parties will sincerely cooperate to properly handle the matters related to the termination of the Cooperation Agreement within 100 days in accordance with the agreed terms, including: 1. Both parties terminate any unfulfilled commitments and stop any activities related to the vaccine (in view of the current Phase II clinical trial of the HPV9-AS04 candidate vaccine
Beijing Wantai Biological Pharmacy Enterprise (603392.SH): Facing the gradual launch of new manufacturers' HPV vaccines, the domestic market for the company's bivalent HPV vaccine has indeed faced considerable pressure.
On July 16th, Gelunhui reported that Beijing Wantai Biological Pharmacy Enterprise (603392.SH) stated on the interactive platform that the domestic market for the company's bivalent HPV vaccine has indeed been under significant pressure in the face of the successive launches of the new manufacturers' HPV vaccines. However, from the perspective of market potential analysis, there is still a high inventory market for women aged 9-45, and the company's bivalent HPV vaccine, as the only domestically produced cervical cancer vaccine that has obtained WHO PQ certification, has specific advantages in terms of its economic value and product quality for certain population. As for the product itself, the company possesses an independent intellectual property right for the technical system of E. coli prokaryotic expression virus-like particle vaccine, which has a high safety profile and strong immunity.
Beijing Wantai Biological Pharmacy Enterprise's announcement of 2024 half-year performance pre-reduction.
Beijing Wantai Biological Pharmacy Enterprise (603392.SH): The net income in the first half of the year is expected to decrease by 85.90% year-on-year to 82.96%.
On July 10th, Gelonhui reported that in the first half of 2024, Beijing Wantai Biological Pharmacy Enterprise (603392.SH) announced a reduction in performance. Preliminary calculations by the finance department showed that net income attributable to the owners of the parent company in the first half of 2024 is expected to be between 0.24 billion yuan and 0.29 billion yuan, a decrease of 85.90% to 82.96% year-on-year, while the net income after deducting non-recurring losses and gains attributable to the owners of the parent company is expected to be between 58 million yuan and 70 million yuan, which is a decrease of 96.43% to 95.69% year-on-year. It is expected that the company's revenue in the second quarter of 2024 will be 5.
Beijing Wantai Biological Pharmacy Enterprise (603392.SH): has accumulated repurchased 0.0879% of shares.
On July 1st, Gelunhui reported that Beijing Wantai Biological Pharmacy Enterprise (603392.SH) has announced that as of June 28, 2024, the company has repurchased 1,115,285 shares through centralized bidding transactions, accounting for 0.0879% of the total share capital. The highest repurchase price was 70.19 yuan/share, the lowest was 45.55 yuan/share, and the total amount of funds paid was RMB 66,388,760.01 (excluding transaction commission and other transaction costs).
No Data
